RZLT Latest Press Releases

-- October 14, 2026 --

Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism Globe Newswire 4:05 PM

-- October 5, 2026 --

Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism Globe Newswire 7:00 AM

-- September 24, 2026 --

Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update Globe Newswire 4:05 PM

-- September 9, 2026 --

Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism Globe Newswire 7:00 AM

-- September 2, 2026 --

Rezolute to Participate in Upcoming Investor Conferences Globe Newswire 7:30 AM

-- July 21, 2026 --

Rezolute to Participate in the BTIG Virtual Biotechnology Conference Globe Newswire 7:30 AM

-- June 17, 2026 --

Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society Globe Newswire 7:00 AM

-- June 4, 2026 --

Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society Globe Newswire 7:30 AM

-- June 2, 2026 --

Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes